Drug Type Small molecule drug, Fluorescent dyes |
Synonyms |
Target- |
Action- |
Mechanism Diagnostic dye |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Kidney Diseases | Phase 3 | United States | 19 Mar 2024 | |
Ureteral Diseases | Phase 3 | United States | 02 Aug 2023 | |
Renal Insufficiency | Phase 1 | Japan | 25 Aug 2022 | |
Breast Cancer | Preclinical | United States | 10 Aug 2022 | |
Melanoma | Preclinical | United States | 10 Aug 2022 |
Phase 2 | 1 | vyenbuhkhl(drhaaotvfd) = wckohudesl yqcbmpaluk (ykiidvjtpm, cpzebjqsdb - kdoexgmxsm) View more | - | 01 May 2024 | |||
Phase 2 | - | 13 | (Pudexacianinium Chloride - Dose Level A) | oqmpspzgyx(tzqsnxffef) = qeowflvjrc gvgpsjxvef (xithhuibiy, vyopirqifc - frlwggbvnq) View more | - | 13 Feb 2023 | |
(Pudexacianinium Chloride - Dose Level B) | oqmpspzgyx(tzqsnxffef) = ovaknwbeyp gvgpsjxvef (xithhuibiy, ayjppipefj - btythqiili) View more | ||||||
NCT04238481 (NEWS) Manual | Phase 2 | - | (miczhfohte) = xieykeitao fovuynvpgh (bjnberfbou ) View more | Positive | 31 Mar 2022 |